ALSO NOTED: Bradley Pharmaceuticals gets bids; Novartis gains patent extension for Diovan;

> Possible buyers have submitted preliminary bids for specialty drug maker Bradley Pharmaceuticals, the company announced. Bids will be evaluated by financial adviser Deutsche Bank and by a special committee of the company's board. Report

> Novartis got a six-month marketing extension on its patent for Diovan, a high blood pressure remedy, to September 2012. The extension applies to pediatric use only, and comes after a study conducted in children with high blood pressure. Release

> Kenya has become the latest country to stop using Viracept, an HIV treatment recalled in Europe after it was contaminated. The June recall has been followed by bans in other countries, including Zambia, which withdrew the drug, manufactured by Roche, last month. Article

> Beset by generic competition for its antidepressant Wellbutrin XL, Biovail says it's placing its chips on new drugs, notably a remedy for sexual dysfunction. That drug, known as BVF-324, was the subject of a recent license-and-development deal that Biovail announced this week. Report

And Finally... The vast majority of seniors now have prescription drug coverage, according to a new study by the University of Michigan. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.